Tocilizumab for juvenile idiopathic arthritis: a single-center case series

Autor: Tülin Güngör, Özlem Aydoğ, Gökçe Can, Fatma Yazılıtaş, Mehmet Bülbül, Dogan Simsek, Evrim Kargın Çakıcı, Semanur Özdel
Přispěvatelé: OMÜ
Rok vydání: 2019
Předmět:
musculoskeletal diseases
Male
medicine.medical_specialty
Adolescent
Interleukin-6 inhibitors
Drug Resistance
Arthritis
Blood Sedimentation
Single Center
Antibodies
Monoclonal
Humanized
03 medical and health sciences
chemistry.chemical_compound
Hemoglobins
0302 clinical medicine
Tocilizumab
Internal medicine
medicine
Leukocytes
Outpatient clinic
Humans
030212 general & internal medicine
skin and connective tissue diseases
Child
Retrospective Studies
business.industry
Platelet Count
Medical record
Retrospective cohort study
General Medicine
Juvenile idiopathic arthritis
medicine.disease
Childhood
Rheumatology
Arthritis
Juvenile
C-Reactive Protein
Treatment Outcome
chemistry
Tolerability
Antirheumatic Agents
Child
Preschool
Medicine
Chronic arthritis
Female
business
030217 neurology & neurosurgery
Zdroj: Sao Paulo Medical Journal v.137 n.6 2019
São Paulo medical journal
Associação Paulista de Medicina
instacron:APM
São Paulo Medical Journal, Vol 137, Iss 6, Pp 517-522 (2020)
ISSN: 1806-9460
Popis: simsek, dogan/0000-0001-8339-9704; Kargin cakici, Evrim/0000-0002-1697-6206; Ozdel, Semanur/0000-0001-5602-4595 WOS: 000528273300008 PubMed: 32159638 BACKGROUND: Juvenile idiopathic arthritis (JIA) is the commonest chronic rheumatic disease among children. When not treated effectively, JIA can lead to functional disability, due to joint damage, along with long-term morbidities. OBJECTIVES: To describe the use of tocilizumab therapy for 11 patients with polyarticular JIA (pJIA) and systemic JIA (sJIA) who presented inadequate response or were refractory to disease-modifying anti-rheumatic drugs (DMARDs) and/or other biological therapies; and to evaluate its benefits, safety and tolerability. DESIGN AND SETTING: Observational retrospective case series at a tertiary-level training and research hospital. METHODS: We reviewed the medical records of 11 consecutive patients with JIA who received tocilizumab (anti-IL-6) therapy in our pediatric nephrology and rheumatology outpatient clinic. We analyzed their demographic data, clinical and laboratory findings, treatment response and adverse reactions. We determined the efficacy of tocilizumab treatment using the American College of Rheumatology (ACR) pediatric (Pedi) response criteria, including ACR Pedi 30, 50, 70 and 90 scores. We used the Wilcoxon test to compare measurements before and after treatment. RESULTS: Tocilizumab was given to seven patients with sJIA and four with pJIA (one of the pJIA patients was rheumatoid factor-positive). In most patients, we observed improvement of symptoms, absence of articular and extra-articular inflammation and continued inactive disease. ACR Pedi 30, 50 and 70 scores were achieved by 90.9% of the patients. Five patients showed minor side effects, possibly due to use of tocilizumab. CONCLUSIONS: Tocilizumab therapy should be considered for treating patients with diagnoses of pJIA or sJIA who are resistant to non-biological DMARDs and/or other biological therapies.
Databáze: OpenAIRE
Externí odkaz: